The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial [version 1; peer review: 2 approved, 1 approved with reservations]
Background: Empagliflozin is an SGLT2 inhibitor approved for use in patients with diabetes mellitus type 2 (DMT2) with or without other cardiovascular disease. Empagliflozin is taken once daily without rationale on the optimal timing for administration. This study aimed to determine the chronopharma...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2021-04-01
|
Series: | F1000Research |
Online Access: | https://f1000research.com/articles/10-321/v1 |
id |
doaj-3d3d1e0e704f4f898ace4a5297903944 |
---|---|
record_format |
Article |
spelling |
doaj-3d3d1e0e704f4f898ace4a52979039442021-06-02T10:58:47ZengF1000 Research LtdF1000Research2046-14022021-04-011010.12688/f1000research.51114.154231The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial [version 1; peer review: 2 approved, 1 approved with reservations]Rana M. ElDash0Mohamed A. Raslan1Sara M. Shaheen2Nagwa Ali Sabri3Pharmacy Practice Department, Faculty of Pharmacy, Heliopolis University, Cairo, 11785, EgyptQuality Control, Drug Research Center, Cairo, EgyptClinical Pharmacy Department, Faculty of Pharmacy, AinShms University, Cairo, 11566, EgyptClinical Pharmacy Department, Faculty of Pharmacy, AinShms University, Cairo, 11566, EgyptBackground: Empagliflozin is an SGLT2 inhibitor approved for use in patients with diabetes mellitus type 2 (DMT2) with or without other cardiovascular disease. Empagliflozin is taken once daily without rationale on the optimal timing for administration. This study aimed to determine the chronopharmacological effects of morning vs evening administration of empagliflozin (10 mg) in healthy Egyptian adults, by investigating the pharmacokinetics and pharmacodynamics parameters of empagliflozin depending on the intake time. Methods: An open label, sequential, two‐way crossover trial comprised of two periods with a washout period of 7 days. All participants received a single oral dose of empagliflozin (JARDIANCE ®; 10 mg film coated tablet) in the evening, and after a seven-day washout period, the morning. Pharmacokinetics parameters (primary endpoints: tmax (h), Cmax (ng/ml), AUC 0-t (ng.h/ml); secondary endpoints: AUC 0 to ∞(ng.h/ml)) were assessed. Method validation was done prior to injection in LC/MS/MS and samples were processed by Liquid-Liquid extraction. The pharmacodynamic profile (UGE 0-24) was determined after method validation (glucose hexokinase method). Results: Tmax increased by 35% in the evening phase compared to the morning phase, while Cmax decreased by -6.5% in the evening dose compared to the morning dose. Additionally, AUC0 to ∞ increased in the evening phase by 8.25% compared to the morning phase. The mean cumulative amount of glucose excreted (UGE (0-24)) increased by 43% in the evening dose compared to the morning dose Conclusion: Despite the difference in pharmacokinetics parameters between evening and morning doses, Cmax, AUC0-t, AUC 0-∞, didn’t differ on the bioequivalence level. In addition, as UGE (0-24) didn’t statistically differ, thus, we can conclude that there is no statistical significance between the morning and evening doses. Trial registration: Clinal Trials.gov, ID: NCT03895229 (registered on 29th March 2019).https://f1000research.com/articles/10-321/v1 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Rana M. ElDash Mohamed A. Raslan Sara M. Shaheen Nagwa Ali Sabri |
spellingShingle |
Rana M. ElDash Mohamed A. Raslan Sara M. Shaheen Nagwa Ali Sabri The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial [version 1; peer review: 2 approved, 1 approved with reservations] F1000Research |
author_facet |
Rana M. ElDash Mohamed A. Raslan Sara M. Shaheen Nagwa Ali Sabri |
author_sort |
Rana M. ElDash |
title |
The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial [version 1; peer review: 2 approved, 1 approved with reservations] |
title_short |
The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial [version 1; peer review: 2 approved, 1 approved with reservations] |
title_full |
The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial [version 1; peer review: 2 approved, 1 approved with reservations] |
title_fullStr |
The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial [version 1; peer review: 2 approved, 1 approved with reservations] |
title_full_unstemmed |
The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial [version 1; peer review: 2 approved, 1 approved with reservations] |
title_sort |
effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial [version 1; peer review: 2 approved, 1 approved with reservations] |
publisher |
F1000 Research Ltd |
series |
F1000Research |
issn |
2046-1402 |
publishDate |
2021-04-01 |
description |
Background: Empagliflozin is an SGLT2 inhibitor approved for use in patients with diabetes mellitus type 2 (DMT2) with or without other cardiovascular disease. Empagliflozin is taken once daily without rationale on the optimal timing for administration. This study aimed to determine the chronopharmacological effects of morning vs evening administration of empagliflozin (10 mg) in healthy Egyptian adults, by investigating the pharmacokinetics and pharmacodynamics parameters of empagliflozin depending on the intake time. Methods: An open label, sequential, two‐way crossover trial comprised of two periods with a washout period of 7 days. All participants received a single oral dose of empagliflozin (JARDIANCE ®; 10 mg film coated tablet) in the evening, and after a seven-day washout period, the morning. Pharmacokinetics parameters (primary endpoints: tmax (h), Cmax (ng/ml), AUC 0-t (ng.h/ml); secondary endpoints: AUC 0 to ∞(ng.h/ml)) were assessed. Method validation was done prior to injection in LC/MS/MS and samples were processed by Liquid-Liquid extraction. The pharmacodynamic profile (UGE 0-24) was determined after method validation (glucose hexokinase method). Results: Tmax increased by 35% in the evening phase compared to the morning phase, while Cmax decreased by -6.5% in the evening dose compared to the morning dose. Additionally, AUC0 to ∞ increased in the evening phase by 8.25% compared to the morning phase. The mean cumulative amount of glucose excreted (UGE (0-24)) increased by 43% in the evening dose compared to the morning dose Conclusion: Despite the difference in pharmacokinetics parameters between evening and morning doses, Cmax, AUC0-t, AUC 0-∞, didn’t differ on the bioequivalence level. In addition, as UGE (0-24) didn’t statistically differ, thus, we can conclude that there is no statistical significance between the morning and evening doses. Trial registration: Clinal Trials.gov, ID: NCT03895229 (registered on 29th March 2019). |
url |
https://f1000research.com/articles/10-321/v1 |
work_keys_str_mv |
AT ranameldash theeffectofmorningversuseveningadministrationofempagliflozinonitspharmacokineticsandpharmacodynamicscharacteristicsinhealthyadultsatwowaycrossovernonrandomisedtrialversion1peerreview2approved1approvedwithreservations AT mohamedaraslan theeffectofmorningversuseveningadministrationofempagliflozinonitspharmacokineticsandpharmacodynamicscharacteristicsinhealthyadultsatwowaycrossovernonrandomisedtrialversion1peerreview2approved1approvedwithreservations AT saramshaheen theeffectofmorningversuseveningadministrationofempagliflozinonitspharmacokineticsandpharmacodynamicscharacteristicsinhealthyadultsatwowaycrossovernonrandomisedtrialversion1peerreview2approved1approvedwithreservations AT nagwaalisabri theeffectofmorningversuseveningadministrationofempagliflozinonitspharmacokineticsandpharmacodynamicscharacteristicsinhealthyadultsatwowaycrossovernonrandomisedtrialversion1peerreview2approved1approvedwithreservations AT ranameldash effectofmorningversuseveningadministrationofempagliflozinonitspharmacokineticsandpharmacodynamicscharacteristicsinhealthyadultsatwowaycrossovernonrandomisedtrialversion1peerreview2approved1approvedwithreservations AT mohamedaraslan effectofmorningversuseveningadministrationofempagliflozinonitspharmacokineticsandpharmacodynamicscharacteristicsinhealthyadultsatwowaycrossovernonrandomisedtrialversion1peerreview2approved1approvedwithreservations AT saramshaheen effectofmorningversuseveningadministrationofempagliflozinonitspharmacokineticsandpharmacodynamicscharacteristicsinhealthyadultsatwowaycrossovernonrandomisedtrialversion1peerreview2approved1approvedwithreservations AT nagwaalisabri effectofmorningversuseveningadministrationofempagliflozinonitspharmacokineticsandpharmacodynamicscharacteristicsinhealthyadultsatwowaycrossovernonrandomisedtrialversion1peerreview2approved1approvedwithreservations |
_version_ |
1721404825313214464 |